Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome.
Diabetes Metab Syndr Obes. 2017 Jan 27;10:47-55. doi: 10.2147/DMSO.S126291. eCollection 2017.
Diabetes Metab Syndr Obes. 2017.
PMID: 28184166
Free PMC article.
Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.
Davies MJ, Merton K, Vijapurkar U, Yee J, Qiu R.
Davies MJ, et al.
Cardiovasc Diabetol. 2017 Mar 21;16(1):40. doi: 10.1186/s12933-017-0517-7.
Cardiovasc Diabetol. 2017.
PMID: 28327140
Free PMC article.
Clinical Trial.
Item in Clipboard
Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes.
Merton K, Davies MJ, Vijapurkar U, Inman D, Meininger G.
Merton K, et al.
Curr Med Res Opin. 2018 Feb;34(2):313-318. doi: 10.1080/03007995.2017.1391759. Epub 2017 Nov 16.
Curr Med Res Opin. 2018.
PMID: 29022746
Clinical Trial.
Item in Clipboard
Cite
Cite